I-Corps: Transforming Personalized Medicine With Printed Medicine

I-Corps：通过印刷医学改变个性化医疗

• 批准号: 1644609
• 负责人: Gintaras Reklaitis
• 金额: $ 5万
• 依托单位: Purdue University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1644609&HistoricalAwards=false
• 关键词: Corps; Transforming; Personalized; Medicine; Printed

The broader impact / commercial potential of this I-Corps project is to completely transform personalized medicine. With this technology in a compounding pharmacy or hospital clinical pharmacy, a patient can be prescribed a one-off combination of drug substances in limited quantities, customized for their individual physiology, and the pharmacy can produce such a custom-made product to high quality specifications for that patient within minutes. Patients can be either human or animal, as these challenges exist in both human and animal health. The long-term beneficial consequences of the work proposed will include that : (1) patients will attain stable dosage amounts in hours rather than months; (2) challenging patient subpopulations will have available products tailor-made to their metabolism; (3) known life-saving drugs which hitherto could not be commercialized because of severe shelf life limitations can become viable; and (4) both personalized medicine and pharmaceutical product supply chain will be transformed.This I-Corps project enables personalized medicine. The technology is analogous to an inkjet printer, printing precise quantities of medicine on substrates such as tablets and capsules. Our past research has proven precision printing to be well-matched to pharmaceutical production applications. High-precision microfluidics and process analytical technology have been used to validate both the quantity and quality of pharmaceutical products made by printing, and the proof of concept is well-established. Precision of better than 1% relative standard deviation at the stringent individual dose level is routinely achieved. This project will cause broader adoption of precision production, additive manufacturing, just-in-time production, applied microfluidics, and advanced process management.

该 I-Corps 项目更广泛的影响/商业潜力是彻底改变个性化医疗。利用这项技术，在复方药房或医院临床药房中，可以为患者开出一次性的有限数量的药物组合，并根据其个人生理状况进行定制，并且药房可以按照高质量规格生产这种定制产品几分钟内就可以为该患者提供帮助。患者可以是人类或动物，因为这些挑战在人类和动物健康中都存在。拟议工作的长期有益后果包括：（1）患者将在数小时而不是数月内获得稳定的剂量； (2) 具有挑战性的患者亚群将有适合其新陈代谢的可用产品； (3) 迄今为止由于严格的保质期限制而无法商业化的已知救生药物可以变得可行； (4)个性化医疗和医药产品供应链都将发生转变。I-Corps项目使个性化医疗成为可能。该技术类似于喷墨打印机，可在片剂和胶囊等基材上打印精确数量的药物。我们过去的研究证明精密打印非常适合药品生产应用。高精度微流体和过程分析技术已用于验证印刷药品的数量和质量，并且概念验证已经建立。在严格的个体剂量水平下，通常可以达到优于 1% 相对标准偏差的精度。该项目将促使精密生产、增材制造、准时生产、应用微流体和先进工艺管理得到更广泛的采用。